Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 1000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 250 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 3000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 2000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 500 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 4000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Европейский союз - английский - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - eftrenonacog alfa - hemophilia b - vitamin k and other hemostatics, blood coagulation factors - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 250unit

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 500unit

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 1000unit